Supporting Evidence for Cannabis Killing Cancer Cells

May 22, 2017

Those familiar with the cannabis space will likely be familiar with 'Rick Simpson Oil', or what used to be known as 'hash oil'. This oil is a concentrate of oil from the cannabis plant that contains THC, CBD, and a host of 100+ other cannabinoids and cannabinoid like substances that are extracted from the raw plant material. Cannabinoids all have unique chemical structures and medicinal properties that range from anti-emetic to anti-epileptic.


This oil is some times referred to as 'snake oil' as the idea that cannabis oil can cure cancer is far fetched to most of us. However, there is a growing body of pre-clinical and now clinical evidence to support the theory that cannabinoids can aid in the suppression of tumors via multiple pathways.


There is supporting evidence that suggests flooding the body with cannabinoids like THC and CBD will help treat cancerous tumors. This study here suggests that high concentrations of cannabinoids constitute the preferred regimen for neurosurgeons to use when treating malignant astrocytomas with this class of compounds.




The study referred to in the above paragraph suggests that the high dose cannabinoids flood the body, bypassing the CB1 and CB2 receptors through overflow and provide additional therapeutic benefits for fighting cancer via 'yet unkown' receptors. They proffer the idea that other G coupled protein receptors (GPR55) are involved and that is likely the case. However, additional receptors (PPAR) seem to also be involved and they are the nuclear receptors.


PPAR receptors are nuclear hormone receptors and have gained a lot of attention due to their role in various malignancies, including lung cancer.

  • PPARα activation generally inhibits tumorigenesis through its antiangiogenic and anti-inflammatory effects

  • Activated PPARγ is also antitumorigenic and antimetastatic, regulating several functions of cancer cells and controlling the tumor microenvironment

  • CBD also promotes PPARa activity by inhibiting FAAH. FAAH is a metabolic enzyme that breaks down several cannabinoid compounds including THC.

So, we know that THC activates PPAR receptors through this and other studies.


However, the latest evidence for cannabinoids and their role in treating cancer comes from a study just completed on humans. This was a two-part study in patients with recurrent GBM (brain cancer) following standard chemo-radiotherapy treatment. There were no Grade 3 or 4 toxicities in Part 1 of the study.


In conclusion, the above referenced randomized study provides preliminary evidence that 1:1 CBD:THC offers some efficacy in patients with recurrent GBM when used as an adjunct to dose-intense temozolomide and confirms the safety and feasibility of individualized dosing.


Look for further clinical evidence of the efficacy of cannabinoid therapy in cancer in the coming months from the biotech world.



Please reload

Featured Posts

Cannabis Treats Brain Cancer Effectively in FDA Trial for Humans

February 9, 2017

Please reload

Recent Posts
Please reload

Search By Tags
Please reload

Follow Us
  • Facebook Classic
  • Twitter Classic
  • Google Classic


Loren DeFalco, President


Follow me:

  • Twitter Clean
  • w-blogger
RSS Feed

© 2015 by The ECS Solution

The content on including but not limited to text, graphics, images, RSS feeds, links and all other material contained on the website is intended for your general knowledge and education only and is NOT a substitute for medical advice or treatment for a specific medical condition.

Any information contained on is not intended to diagnose, prevent, treat or cure any disease.

In no way are you to consider the information I offer as medical advice, nor does it constitute a doctor/patient relationship.

Never disregard professional medical advice or delay in seeking it because of something you have read on or any other website(s) linked to it.